Congressional Democrats Press US FDA For Transparency In Review Of COVID-19 Vaccines

FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.

Covid_2019_Vaccine
Congress gives FDA advice on COVID-19 vaccine clinical trials • Source: Shutterstock

The US Food and Drug Administration is facing pressure from Congress over how to handle the forthcoming flurry of applications for COVID-19 vaccines. A subcommittee of the House Oversight and Reform Committee is demanding that the agency commit to having its Vaccines and Related Biological Products Advisory Committee (VRBPAC) evaluate all the vaccine candidates FDA reviews.

The Subcommittee on Economic and Consumer Policy held a virtual briefing on 14 July to spotlight what it believes FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet